Information | H | RA# | LS | Non-LS | SA |
BALF/serum/plasma | 12/12/0 | 0/8/6 | 12ƒ/12/0 | 12/12/0 | 0/20/0 |
Age years | 27±3 | 55±16 | 42±7 | 43±9 | 49±11 |
Never-smokers/ex-smokers | 12/0 | NA | 8/3 | 9/3 | 17/3 |
Males/females | 12/0 | 7/6 | 12/0 | 12/0 | 1/19 |
Radiographic stage I/II/III/IV¶ | NA | NA | 5/6/0/0 | 3/9/0/0 | NA |
FVC+ % of predicted | 114±11 | NA | 84±16 | 90±14 | 102±23 |
FEV1 % of predicted | 107±9 | NA | 86±16 | 86±15 | 82±20 |
FEV1/FVC§ | 79±7 | NA | 78±7 | 70±6 | 69±9 |
Data are presented as n or mean±sd. For additional information, see supplementary table 1. H: healthy controls; RA: rheumatoid arthritis; LS: Löfgren's syndrome; SA: severe asthma; BALF: bronchoalveolar lavage fluid; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; NA: not available. #: information obtained from published data [13]. ¶: stage I indicates granuloma formation in the hilar lymph nodes; stage II also has, in addition to the hilar lymphadenopathy, granuloma formation in the lung shown as diffuse infiltrates on the radiograph; stage III has parenchymal infiltrates on the radiograph but absence of hilar adenopathy; stage IV indicates irreversible pulmonary scarring. +: LS group is missing one value. §: LS group is missing one value; non-LS group is missing three values. ƒ: LS group contains two different BALF samples from the same patient.